Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Ling-ling Zhu¹
Zhi-jun Feng²
Quan Zhou³

¹Geriatric VIP Ward, Division of Nursing, ²Department of Urology Surgery, ³Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China

Dear editor

We read with great interest the multicenter, prospective, comparative cohort study by Zhang et al¹ who suggested that patients with uncontrolled or untreated hypertension and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) should be warned about a decrease in blood pressure on initiation of alfuzosin 10 mg therapy alone or concomitantly with antihypertensive medication. Here we discuss and share our perspectives on this issue.

α₁-blockers are the most frequently prescribed medical therapy in the treatment of BPH/LUTS. A number of α₁-blockers (alfuzosin, doxazosin, terazosin, tamsulosin, naftopidil, silodosin) have been approved for the treatment of BPH throughout the world; however, they exhibit different selectivity toward α₁-adrenoceptor (AR) subtypes. Three types of α₁-AR subtypes (α₁A, α₁B, and α₁D) are found in human tissue. The α₁A subtype is located in the human prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, and mediates contraction of the smooth muscle in these tissues. In addition to α₁A-ARs, α₁B-ARs are also present to a significant extent in the human prostate, and α₁D-ARs are thought to mediate contraction of human arteries.²

The early α₁-blockers (alfuzosin, doxazosin, terazosin) were nonselective for subtype and were associated with blood pressure-related adverse effects, such as orthostatic hypotension.³ Sato et al compared the binding affinity of tamsulosin for human α₁-AR subtypes with that of other α₁-blockers, ie, silodosin, terazosin, alfuzosin, and naftopidil.⁴ Tamsulosin has relative selectivity for the α₁A-subtype and α₁D-subtype (α₁A = α₁D > α₁B), and naftopidil has relative selectivity for the α₁B-subtype (α₁B ≥ α₁A > α₁D). The affinity of tamsulosin for the human α₁A-AR was, respectively, 5-fold, 120-fold, 280-fold, and 400-fold higher than that of silodosin, terazosin, alfuzosin, and naftopidil, respectively. However, the α₁B-AR binding affinity of silodosin was shown to be much lower than that of tamsulosin in vitro.⁵ The selectivity of silodosin towards the α₁A-AR subtype versus the α₁D-AR subtype (α₁A > α₁D > α₁B) was reported to be 38-fold higher than that of tamsulosin in studies using transgenic Chinese hamster ovary cells.⁶,⁷ The selectivity ratio (α₁A/α₃B) for terazosin, doxazosin, alfuzosin, tamsulosin, and silodosin was 0.3, 0.4, 0.5, 6.3, and 166, respectively.⁸ The unique AR selectivity profile of silodosin minimizes the propensity for blood pressure-related adverse effects caused by α₁A-AR blockade.⁹ Regarding the efficacy of subtype-selective α₁-blockers in the management of BPH, expression of α₁A-AR subtype mRNA was observed as a predictor. Tamsulosin hydrochloride was more effective in patients with dominant

Correspondence: Quan Zhou
Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Tel +86 571 8787 4615
Fax +86 571 8702 2776
Email zhouquan142602@zju.edu.cn

This article was published in the following Dove Press journal:
Clinical Interventions in Aging
26 March 2015
Number of times this article has been viewed
expression of the $\alpha_{1A}$-AR subtype, whereas naftopidil was more effective in those with dominant expression of the $\alpha_{1D}$-AR subtype.\textsuperscript{10}

With respect to the indications for $\alpha_{1}$-blockers, doxazosin and terazosin are currently indicated for the treatment of both hypertension and BPH/LUTS, and are more likely to impair safety-relevant physiological blood pressure control in normotensives with LUTS than are tamsulosin and silodosin.\textsuperscript{11,12} Alfuzosin is only indicated for treatment of BPH/LUTS. The study by Zhang et al demonstrated that alfuzosin 10 mg has no clinically important effects on blood pressure when used to treat BPH/LUTS in men who were physiologically normotensive or had hypertension controlled by antihypertensive medication. The relevance of their finding is that it provides reassurance for clinicians when prescribing alfuzosin 10 mg for a patient who is already on antihypertensive therapy, without the need to worry about the risk of hypotensive episodes. However, alfuzosin 10 mg significantly decreased blood pressure in patients with uncontrolled or untreated hypertension, indicating that such patients require careful evaluation before initiating alfuzosin therapy.\textsuperscript{1} The study by Zhang et al further indicates that the clinical selectivity and cardiovascular safety of $\alpha_{1}$-blockers are related to patient-treatment interactions (comedication and comorbidity), and their finding will enrich our knowledge about the personalized therapeutics of $\alpha_{1}$-blockers in the treatment of BPH/LUTS.\textsuperscript{1} However, the vasodilatory adverse events of alfuzosin are related to dose, dosage interval, and formulation, ie, they are less frequent with once-daily, sustained-release alfuzosin 10 mg than with the three times daily 2.5 mg formulation (6.3% versus 9.4%, respectively).\textsuperscript{13} Therefore, clinicians should be cautious about extrapolating the finding of the study by Zhang et al to treatment of BPH/LUTS with an immediate-release formulation of alfuzosin.\textsuperscript{1}

**Acknowledgment**

This work was supported by the Zhejiang Provincial Bureau of Health (2012KYA090).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Zhang LT, Lee SW, Park K, et al. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications. *Clin Interv Aging*. 2015;10:277–286.

2. Sohn JT, Ding X, McCune DF, Perez DM, Murray PA. Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contraction. *Anesthesiology*. 2005;103:327–334.

3. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. *Int J Urol*. 2008;15:193–199.

4. Sato S, Hatanaka T, Yuyama H, et al. Tamsulosin potently and selectively antagonizes human recombinant $\alpha$(1A/1D)-adrenoceptors: slow dissociation from the $\alpha$(1A)-adrenoceptor may account for selectivity for $\alpha$(1A)-adrenoceptor over $\alpha$(1B)-adrenoceptor subtype. *Biol Pharm Bull*. 2012;35:72–77.

5. Yamada S, Ito Y, Tsukada H. $\alpha$1-Adrenoceptors and muscarinic receptors in voiding function—binding characteristics of therapeutic agents in relation to the pharmacokinetics. *Br J Clin Pharmacol*. 2011;72:205–217.

6. Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. *Clin Interv Aging*. 2011;6:161–172.

7. Schwinn DA, Price DT, Narayan P. Alpha1-adrenoceptor subtype selectivity and lower urinary tract symptoms. *Mayo Clin Proc*. 2004;79:1423–1434.

8. Yamada S, Ito Y. $\alpha$1-adrenoceptors in the urinary tract. *Handb Exp Pharmacol*. 2011;202:283–306.

9. Lepor H, Kazzazi A, Djavan B. $\alpha$-blockers for benign prostatic hyperplasia: the new era. *Curr Opin Urol*. 2012;22:7–15.

10. Kojima Y, Sasaki S, Kubota Y, et al. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. *J Urol*. 2008;179:1040–1046.

11. de Mey C. Alpha(1)-blockers for BPH: are there differences? *Eur Urol*. 1999;36 Suppl 3:52–63.

12. Capitanio U, Salonia A, Briganti A, Montorsi F. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates? *Int J Clin Pract*. 2013;67:544–551.

13. van Kerrebroeck P, Jardin A, Laval KL, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostate hyperplasia. ALFORTI Study Group. *Eur Urol*. 2000;37:306–313.
Alpha₁-receptors are abundant in the smooth muscle of the prostate and bladder, and α₁-blockers produce a reduction in smooth muscle tone. Of the three α-blocker subtypes (α₁A, α₁B, and α₁D), α₁A is considered to be the major regulator of smooth muscle tone in the prostate and bladder neck. In contrast, the α₁B subtype regulates blood pressure via arterial smooth muscle relaxation, while the α₁D subtype is associated with relaxation of the bladder muscle as well as innervation of the sacral spinal cord. The currently available α₁-receptors (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin) differ in their safety profiles but share similar efficacy. Older α₁-blockers (doxazosin and terazosin), which are used to treat both hypertension and LUTS/BPH, are associated with a greater incidence of symptomatic hypotension while silodosin is associated with a higher prevalence of anejaculation ascribed to its selectivity for the α₁A adrenergic receptor at the seminal vesicle and vas deferens. The orthostatic hypotension by α₁-blocker was not frequently but diversely occurred, although the patient took the very low dosage of the medication, which had highly uroselectivity. As such, the concept of a uroselective α₁A adrenergic receptor antagonist has been proposed to reflect the ratio of beneficial urinary effects versus cardiovascular adverse effects such as orthostatic hypotension. Alfuzosin, a novel uroselective antagonist devoid of cardiovascular adverse effects, have been successfully developed in recent years. It is presently available in three formulations: immediate-release alfuzosin 2.5 mg taken three times a day, sustained-release alfuzosin 5 mg taken twice a day, and prolonged-release alfuzosin 10 mg taken once a day.

As early as 2000 years, the cardiovascular safety of alfuzosin 10 mg had never been investigated in patients aged older than 50 years. In the current study, 335 patients were recruited for assessment in daily clinical practice, and it was found that antihypertensive comedication does not affect its cardiovascular adverse effects, have been successfully developed in recent years. It is presently available in three formulations: immediate-release alfuzosin 2.5 mg taken three times a day, sustained-release alfuzosin 5 mg taken twice a day, and prolonged-release alfuzosin 10 mg taken once a day.

As early as 2000 years, the cardiovascular safety of alfuzosin 10 mg had never been investigated in patients aged older than 50 years. In the current study, 335 patients were recruited for assessment in daily clinical practice, and it was found that antihypertensive comedication does not affect its cardiovascular adverse effects, have been successfully developed in recent years. It is presently available in three formulations: immediate-release alfuzosin 2.5 mg taken three times a day, sustained-release alfuzosin 5 mg taken twice a day, and prolonged-release alfuzosin 10 mg taken once a day.

As early as 2000 years, the cardiovascular safety of alfuzosin 10 mg had never been investigated in patients aged older than 50 years. In the current study, 335 patients were recruited for assessment in daily clinical practice, and it was found that antihypertensive comedication does not affect its cardiovascular adverse effects, have been successfully developed in recent years. It is presently available in three formulations: immediate-release alfuzosin 2.5 mg taken three times a day, sustained-release alfuzosin 5 mg taken twice a day, and prolonged-release alfuzosin 10 mg taken once a day.
References

1. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14–26.

2. Oelke M, Bachmann A, Desczaeck A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–140.

3. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–1803.

4. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–547.

5. Hargreave TB, McNeill AS. Acute urinary retention in men: the risks and outcomes with medical therapy. Curr Urol Rep. 2005;6:263–270.

6. Hatano A, Takahashi H, Tamaki M, et al. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723–728.

7. Chapple CR. A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol. 2005;7 Suppl 4:S22–S30.

8. Schwinn DA, Michelotti GA. Alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of aging on vascular expression. BJU Int. 2000;85 Suppl 2:6–11.

9. Keating GM. Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs. 2015;75:207–217.

10. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176:1529–1533.

11. Andersson KE, Wyllie MG. Ejaculatory dysfunction: why all alpha-blockers are not equal. BJU Int. 2003;92:876–877.

12. Hofner K, Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol. 2002;19:405–412.

13. Andersson KE. The concept of uroselectivity. Eur Urol. 1998;33 Suppl 2:7–11.

14. McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62:633–653.

15. van Kerrebroeck P, Jardin A, Laval KU, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37:306–313.

16. Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014;13:1187–1197.